Outlook Therapeutics Shares NORSE EIGHT Results And BLA Submission In Virtual Investor “What This Means” Segment

Outlook Therapeutics has reached a significant milestone, securing approval in the EU and UK for the first ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). Today, the company announced its participation in the Virtual Investor “What This Means” segment. The Virtual Investor “What This Means” segment featuring Outlook Therapeutics is now available on the company website.

In the segment, Dr. Jennifer Kissner, SVP of Clinical Development, discusses the insights into the 12-week safety and efficacy results from the NORSE EIGHT trial. This marks the second pivotal study assessing ONS-5010 for wet AMD. She also puts forth the company’s plan to resubmit its Biologics License Application (BLA) for ONS-5010 in early 2025, aiming to bring this innovative treatment option to more patients.